NCT02493426View on ClinicalTrials.gov

Single Dose Intranasal Oxytocin and Cognitive Effects in Autism

PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

March 31, 2021

Study Completion Date

March 31, 2021

Conditions
Autism Spectrum Disorders
Interventions
DRUG

Intranasal Oxytocin

DRUG

Placebo

Trial Locations (1)

55414

Center for Neurobehavioral Development, Minneapolis

All Listed Sponsors
lead

University of Minnesota

OTHER

NCT02493426 - Single Dose Intranasal Oxytocin and Cognitive Effects in Autism | Biotech Hunter | Biotech Hunter